CRISPR Therapeutics AG

CRISPR Therapeutics AGverified

CRSP

Price:

$40.79

Market Cap:

$3.48B

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell d...[Read more]

Industry

Biotechnology

IPO Date

2016-10-19

Stock Exchange

NASDAQ

Ticker

CRSP

The PE Ratio as of December 2024 (TTM) for CRISPR Therapeutics AG (CRSP) is -14.62

According to CRISPR Therapeutics AG’s latest financial reports and current stock price. The company's current PE Ratio is -14.62. This represents a change of 212.58% compared to the average of -4.68 of the last 4 quarters.

CRISPR Therapeutics AG (CRSP) Historical PE Ratio (quarterly & annually)

How has CRSP PE Ratio performed in the past?

The mean historical PE Ratio of CRISPR Therapeutics AG over the last ten years is -11.07. The current -14.62 PE Ratio has changed 13.10% with respect to the historical average. Over the past ten years (40 quarters), CRSP's PE Ratio was at its highest in in the December 2017 quarter at 1.91K. The PE Ratio was at its lowest in in the December 2020 quarter at -25.08.

Quarterly (TTM)
Annual

Average

-11.07

Median

-12.22

Minimum

-60.71

Maximum

49.55

CRISPR Therapeutics AG (CRSP) PE Ratio by Quarter and Year

Discovering the peaks and valleys of CRISPR Therapeutics AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 564.18%

Maximum Annual PE Ratio = 49.55

Minimum Annual Increase = -696.60%

Minimum Annual PE Ratio = -60.71

Quarterly (TTM)
Annual
YearPE RatioChange
2023-32.28564.18%
2022-4.86-131.90%
202115.24-152.65%
2020-28.94-158.41%
201949.55-696.60%
2018-8.31-39.51%
2017-13.7328.29%
2016-10.70-33.03%
2015-15.98-73.67%

CRISPR Therapeutics AG (CRSP) Average PE Ratio

How has CRSP PE Ratio performed in the past?

The current PE Ratio of CRISPR Therapeutics AG (CRSP) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-7.30

5-year avg

-0.26

10-year avg

-11.07

CRISPR Therapeutics AG (CRSP) PE Ratio vs. Peers

How is CRSP’s PE Ratio compared to its peers?

CRISPR Therapeutics AG’s PE Ratio is greater than Beam Therapeutics Inc. (-16.59), less than Editas Medicine, Inc. (-0.48), less than Caribou Biosciences, Inc. (-1.02), less than Verve Therapeutics, Inc. (-2.49), less than Intellia Therapeutics, Inc. (-2.35), less than Fate Therapeutics, Inc. (-1.08), less than Regeneron Pharmaceuticals, Inc. (16.51), less than Novo Nordisk A/S (29.27), less than Sarepta Therapeutics, Inc. (95.32), less than CohBar, Inc. (-0.13), less than Hepion Pharmaceuticals, Inc. (-0.15), less than Rain Therapeutics Inc. (-1.51), less than Krystal Biotech, Inc. (87.47), less than AVROBIO, Inc. (2.07),

Build a custom stock screener for CRISPR Therapeutics AG (CRSP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CRISPR Therapeutics AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CRISPR Therapeutics AG (CRSP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CRISPR Therapeutics AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is CRISPR Therapeutics AG's PE Ratio?

How is the PE Ratio calculated for CRISPR Therapeutics AG (CRSP)?

What is the highest PE Ratio for CRISPR Therapeutics AG (CRSP)?

What is the 3-year average PE Ratio for CRISPR Therapeutics AG (CRSP)?

What is the 5-year average PE Ratio for CRISPR Therapeutics AG (CRSP)?

How does the current PE Ratio for CRISPR Therapeutics AG (CRSP) compare to its historical average?